Claims
- 1. A compound having the formula:
- 2. A compound having the formula:
- 3. An antiviral compound selected from the group consisting of syn-2-amino-6-methoxy-N9-(2-hydroxymethylcyclopropylidenemethyl)purine syn-2-amino-6-azido-N9-(2-hydroxymethylcyclopropylidenemethyl)purine and pharmaceutically acceptable salts, and prodrugs, thereof.
- 4. The antiviral compound of claim 3, wherein the compound is the R- or S-enantiomer.
- 5. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 6. A composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.
- 7. A composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.
- 8. A composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.
- 9. A method of treating a mammal infected with a virus comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of claim 1, and combinations thereof.
- 10. The method of claim 9, wherein said mammal is a human.
- 11. The method of claim 9, wherein said virus is selected from the group consisting of a human herpes virus, a human immunodeficiency virus and hepatitis B virus.
- 12. The method of claim 9, further comprising the step of administering an additional antiviral compound.
- 13. The method of claim 12, wherein the additional antiviral compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddl, ddC, 3TC, d4T, and combinations thereof.
- 14. A method of treating a mammal infected with a virus comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of claim 2, and combinations thereof.
- 15. The method of claim 14, wherein said mammal is a human.
- 16. The method of claim 14, wherein said virus is selected from the group consisting of a human herpes virus, a human immunodeficiency virus and hepatitis B virus.
- 17. The method of claim 14, further comprising the step of administering an additional antiviral compound.
- 18. The method of claim 17, wherein the additional antiviral compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddl, ddC, 3TC, d4T, and combinations thereof.
- 19. A method of treating a mammal infected with a virus comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of claim 3, and combinations thereof.
- 20. The method of claim 19, wherein said mammal is a human.
- 21. The method of claim 19, wherein said virus is selected from the group consisting of a human herpes virus, a human immunodeficiency virus and hepatitis B virus.
- 22. The method of claim 19, further comprising the step of administering an additional antiviral compound.
- 23. The method of claim 22, wherein the additional antiviral compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddl, ddC, 3TC, d4T, and combinations thereof.
- 24. A method of treating a mammal infected with a virus comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of claim 4, and combinations thereof.
- 25. The method of claim 24, wherein said mammal is a human.
- 26. The method of claim 24, wherein said virus is selected from the group consisting of a human herpes virus, a human immunodeficiency virus and hepatitis B virus.
- 27. The method of claim 24, further comprising the step of administering an additional antiviral compound.
- 28. The method of claim 27, wherein the additional antiviral compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddl, ddC, 3TC, d4T, and combinations thereof.
RELATED APPLICATIONS
[0001] The present invention is a continuation-in-part of PCT International Application No. PCT/US98/00440, filed Jan. 7, 1998, designating the United States, which claims priority from U.S. Serial No. 60/035,826, filed Jan. 8, 1997 and U.S. Serial No. 60/045,676, filed May 6, 1997, all of which are hereby expressly incorporated by reference.
SPONSORSHIP
[0002] Work on this invention was supported in part by the National Cancer Institute, Grant No. RO1 CA32779 and National Institute Of Allergy And Infectious Diseases, Grant Nos. U19 Al 31718 and RO1 A133332. The Government has certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60035826 |
Jan 1997 |
US |
|
60045676 |
May 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09267839 |
Mar 1999 |
US |
Child |
10047202 |
Jan 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US98/00440 |
Jan 1998 |
US |
Child |
09267839 |
Mar 1999 |
US |